
Christian Rolfo/X
Jun 8, 2025, 17:00
Christian Rolfo Highlighted VISION Trial Findings on METex14 NSCLC Detection Using Liquid and Tissue Biopsies
Christian Rolfo, Director of the Division of Medical Oncology and Associate Director of Early Phase Clinical Trials at James Comprehensive Cancer Center, shared a post on X:
“Our paper in Clinical Cancer Research is out “Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC : Analyses from the Phase II VISION trial of Tepotinib”Analyses from the Phase II VISION trial of Tepotinib” important liquid biopsy application.”
More posts featuring Christian Rolfo on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 16:53